Celularity reported revenue of $3.85M and net income of -$10.42M for the quarter ended Mar 2026, down 66.3% year over year. This income statement covers 29 quarters of results from Mar 2019 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||
| Revenue | 3.20M | 10.62M | 4.86M | 5.93M | 3.78M | 4.13M | 4.13M | 3.94M | 2.94M | 3.79M | 12.11M | 14.68M | 12.11M | 9.30M | 18.13M | 11.43M | 5.74M | 5.28M | 4.10M | 3.85M | |||||||||
| Cost of RevenueCost of Rev | 1.44M | 2.31M | 4.66M | 4.03M | 3.18M | 7.21M | 5.25M | 2.00M | 0.80M | 3.60M | 9.61M | 1.64M | 2.12M | 3.88M | 7.34M | 3.55M | 5.24M | 3.90M | 7.37M | 1.45M | |||||||||
| Gross Profit | 1.76M | 8.31M | 0.20M | 1.91M | 0.60M | -3.08M | -1.12M | 1.93M | 2.14M | 0.18M | 2.50M | 13.04M | 9.99M | 5.41M | 10.79M | 7.87M | 0.49M | 1.38M | -3.27M | 2.39M | |||||||||
| Operating items | |||||||||||||||||||||||||||||
| Amortization - Intangibles | 0.55M | 0.55M | 0.55M | 0.54M | 0.55M | 0.55M | 0.55M | 0.54M | 0.55M | 0.55M | 0.55M | 0.55M | 0.46M | 0.38M | 0.38M | 0.37M | 0.37M | ||||||||||||
| Research & DevelopmentR&D | 22.91M | 23.77M | 24.69M | 21.67M | 25.35M | 20.35M | 10.99M | 16.95M | 8.60M | 5.18M | -0.27M | 5.84M | 3.80M | 3.92M | 3.83M | 3.73M | 3.35M | 4.60M | 3.35M | 2.99M | |||||||||
| Selling, General & AdministrativeSG&A | 28.86M | 21.64M | 13.21M | 16.46M | 15.57M | 14.91M | 19.08M | 13.93M | 12.83M | 10.75M | 13.07M | 14.03M | 15.91M | 12.65M | 16.06M | 14.26M | 12.63M | 9.31M | 15.06M | 9.16M | |||||||||
| Other Operating ExpensesOther Opex | 12.03M | -45.69M | -18.09M | 9.42M | -41.32M | -25.48M | -43.43M | 36.92M | 23.98M | 87.11M | -14.00M | 2.19M | 2.58M | 4.26M | 7.53M | 3.92M | 5.61M | 4.28M | 7.75M | 1.82M | |||||||||
| Operating ExpensesOpex | 63.81M | -0.28M | 19.81M | 47.55M | -0.40M | 9.78M | -13.36M | 67.81M | 45.41M | 103.04M | -1.20M | 22.06M | 22.29M | 20.82M | 27.41M | 21.91M | 21.60M | 18.18M | 26.16M | 13.98M | |||||||||
| Operating IncomeOp. Inc | -60.61M | 10.90M | -14.95M | -41.61M | 4.17M | -5.65M | 17.48M | -63.87M | -42.48M | -99.26M | 13.31M | -7.38M | -10.18M | -11.53M | -9.28M | -10.49M | -15.86M | -12.90M | -22.06M | -10.13M | |||||||||
| EBIT | -10.13M | ||||||||||||||||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 2.44M | 0.35M | |||||||||||||||||||||||||||
| Goodwill impairment chargesGoodwill Impair. | 3.61M | 29.63M | 82.71M | ||||||||||||||||||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | |||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.08M | 0.06M | |||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.61M | ||||||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | 11.01M | ||||||||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||
| EBT | -10.42M | ||||||||||||||||||||||||||||
| Tax ProvisionsTaxes | 0.04M | 0.02M | 0.02M | -0.02M | 0.01M | 0.01M | |||||||||||||||||||||||
| Profit After TaxPAT | -10.42M | ||||||||||||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -10.42M | ||||||||||||||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -10.42M | ||||||||||||||||||||||||||||
| Income towards Parent CompanyParent Net Inc | 0.87M | ||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | 0.68M | ||||||||||||||||||||||||||||
| Additional items | |||||||||||||||||||||||||||||
| EPS (Basic) | 0.02 | ||||||||||||||||||||||||||||
| EPS (Diluted) | 0.02 | ||||||||||||||||||||||||||||
| Shares Outstanding | 29.07M | ||||||||||||||||||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 30.30M | ||||||||||||||||||||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 29.18M | ||||||||||||||||||||||||||||
| EBITDA | -8.54M | ||||||||||||||||||||||||||||
| Tax Rate | 0.04% | 0.05% | 0.10% | ||||||||||||||||||||||||||
| Interest ExpensesInt Expense | 2.44M | 0.35M |
Pull Celularity's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=CELU&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "CELU", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=CELU&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();